WARRIEWOOD, Australia - AussieJournal -- AXT is proud to announce the addition of Alvéole and their unique bioengineering platform for cell biology to their cutting-edge product portfolio. The Alvéole platform allows you to convert your existing microscope into an automated bioengineering system for the engineering of smart cell culture substrates.

Alvéole is a French based manufacturer specialising in designing tools for engineering more reliable and reproducible in vitro cell microenvironments. This allows researchers working in areas such as proteins and drug discovery to take control of the cellular microenvironment by giving them improved control over experimental conditions. In doing so, they can produce in vivo-like environments that accelerate cell biology research by producing cell studies with increased relevance.

More on Aussie Journal

• Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
• OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
• Trent Williams Expands Life Beyond Debts with Practical Resources for Australians
• P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
• DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials

Their platform can be retrofitted to existing or new inverted light microscopes allowing you to study precise cellular interactions in your laboratory. Cells can be imaged under complex and closely controlled environments that are easily reproducible, making it an ideal biological research tool.

Recent expansion of the portfolio also the Alvéole micropatterning system to be used to precisely pattern cellular location of TEM grids, expanding the ease of use in cryo-electron microscopy imaging and analysis.

Alvéole was founded in 2010 by a team of industry experts who recognised the need for a new in vitro model that more accurately mimics in vivo conditions and thus, accelerate the research and development pathway. Bringing together expertise is in bioengineering, cellular imaging and nanostructures and nanofabrication, Alvéole was formed. Their work to date has culminated in their platform which involves a micropatterning technique that results in cell studies with increased relevance and ease-of-use.

More on Aussie Journal

• French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
• LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
• Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
• STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
• Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice

Hélène Delobel, Sales Operation Manager said, "The Alvéole platform is a unique and intuitive tool that can orchestrate, organise and control the cellular environment that results in an in vitro model that better mimics in vivo conditions. We are very proud of our technology and our new distribution agreement with AXT".

Richard Trett, Managing Director at AXT replied, "Alvéole's innovative platform has synergies with our existing protein and microscopy product lines and we see great potential for it in areas such as biotherapeutics and Cryo-electron microscopy."

For more information on Alvéole's bioengineering platform or indeed any of AXT's protein or microscopy product lines, please visit https://www.axt.com.au.